Boston, Massachusetts 2021-10-26 04:50:06 –
ONe, a major company competing to develop psychedelics as forensic medicine Obtained a patent Last week, a decision was made to formulate the prescription of psilocybin, a hallucinogen found in magic mushrooms, to highlight an increasingly fierce battle for intellectual property over potential medicines in this fast-growing field. ..
This is Compass Pathways’ fourth US patent, but the first in the form of psilocybin that the company has not used in clinical trials for treatment-resistant depression. Mason Marks, Senior Fellow and Project Leader for Harvard Law School’s Psychedelic Law and Regulation Project, said the patent works to “expand the kingdom of intellectual property.” We are trying to lock as many IPs as possible to solidify our position in the market. “
Covering the form of synthetic psilocybin known as “Form A Hydrate” and how it is made, this patent helps the compass as a way to limit competitors who may be using different forms of psilocybin. If another company uses that particular structure to create psilocybin, the compass has a basis for blocking them.
“There is no doubt that the reason behind this is to protect the competitiveness around psilocybin,” said Graham Pechenik, a patent attorney and founder of Calyx Law. The latest patent decisions can be challenged by those who believe that Form A hydrate is not new and cannot be patented.
Compass upheld the decision to seek a patent for its formulation. “As always, we look forward to the challenge,” said Lars Christian Wilde, co-founder and president of Compass. “We believe that what we find is novel and original …. We are confident in our IP strategy.”
Psychedelic research and investment It has been accelerating in recent years. The US Food and Drug Administration has given psilocybin and MDMA (also known as Molly or Ecstasy) breakthrough therapy designations for the treatment of depression and PTSD, respectively. It’s a trial and safe. The potential market is huge and very lucrative and is projected to be valued at $ 7 billion by 2027. According to analysis From Databridge Market Research.
However, both psychedelic drugs exist in nature and have been studied for decades. MDMA was first synthesized in 1912 and psychedelics were synthesized in 1938. Competitors. Instead, companies are creating more niche patents, such as compass IPs for various forms of psilocybin. “We need to understand how to protect this naturally occurring substance,” said Nina Bitritto Garg, an analyst at Citi. (Citigroup receives compensation for investment banking and other services from Attai Life Sciences, which owns more than 20% of the compass.)
There is also considerable debate and competition within the industry as to whether these drugs should be patented and how they should be patented. By the end of this year, Compass will publish the results of a phase 2b trial of 233 patients on psilocybin therapy for treatment-resistant depression. Meanwhile, the anti-patent, non-profit Usona Institute is conducting Phase 2b psilocybin trials in people with major depressive disorder.
Carey Turnbull, a philanthropist who is a board member of several psychedelic nonprofits, including the Usona Institute, has created another nonprofit, Freedom to Operate, to combat patents. Infringe existing knowledge.. He believes that the latest compass patent should not hold.
“Ongoing research at the FTO has shown that it is nearly impossible not to crystallize psilocybin to obtain this hydrate,” Turnbull wrote in STAT. “Prior art has some examples of it.” He declined to give details of existing examples while still compiling the report.
President Bill Lynton said Usona himself was not worried that the psilocybin patent would affect his work. Nonprofits are using versions of the drug that have been in the public domain since 1958.
Psychedelic patents are currently very confusing, with a wave of applications and challenges. This is because many patent examiners are not familiar with space and existing research. The Usona Institute is currently building a library of existing research. Porta Sophia Psychedelic Prior Art LibraryHelps prevent patents from being granted based on existing knowledge. Given that psilocybin was first synthesized in the 1930s and there are many laboratories, Marks said it was doubtful if there was a truly new formulation left to obtain a patent.
Among the psychedelic patents that meet novelty’s technical definition, the rush to protect the drug to prevent competition, rather than patenting innovation that helps patients, is the spirit of intellectual property law. Marks said it was against. Although US patent law requires technical practicality, it rarely applies in practice. “In fact, it doesn’t exist.”In other countries, such as India, Marks is much more strict about creating patents that help patients. Future Harbor Draw Review Forum on Psychedelic Patents..
“It may be some kind of useless patent,” Marks said of the latest compass patent. “I don’t think it brings real benefits.”
Different formulations of psilocybin can have different levels of efficacy, and the Wilde of Compass said it is investigating whether the latest forms are particularly beneficial under certain conditions.
In his view, all patents are informative. IP allows businesses to protect innovation, fund research, and deliver medicine to patients. “Therefore, every patent is in the interests of the patient and, more broadly, in this area.”
Opponents argue that the few companies that own the rights to these drugs will make approved treatments more expensive. For example, if the FDA approves psilocybin according to the Compass Pathways study, only the patented synthetic version of the drug, not the naturally occurring substance, will be forensic. “It impacts the barriers to entry into scientific research and the cost of accessing these therapies,” says Marks.
An important issue for investors is whether the patent is approved and can withstand the challenges. Citi’s Bitrit Guard said ethical issues were less of a concern and that “investors are pursuing profits.”
As a result, psilocybin is slowly moving towards pharmaceutical approval, which can intensify the conflict over all lines of intellectual property. The final patent decision will determine who controls the supply of psilocybin and who will benefit from this hallucinogen.
Psilocybin patent highlights the swirling battle over psychedelics IP Source link Psilocybin patent highlights the swirling battle over psychedelics IP